"The Report PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Description
PharmaPoint: Macular Edema and
Macular Degeneration - Japan Drug Forecast and Market Analysis to
2023
Summary
Macular Edema is a condition
where fluid accumulates on the macula, leading to vision impairment
or in severe cases even vision loss. The three main types of ME are
diabetic macular edema (DME), and macular edema following either a
central or branch retinal vein occlusion (ME-CRVO and ME-BRVO).
Age-related macular degeneration (AMD) is a painless eye condition
which leads to gradual, irreversible, loss of central vision, and is
one of the leading causes of blindness among people aged 50 and over
in the developed world. Currently the ME and AMD markets are
dominated by the use of anti-VEGF monotherapy, however, in recent
years, corticosteroid implants have been reaching the ME market which
could challenge the stronghold these drugs have in this sector. The
AMD market will see the arrival of the first therapies to treat dry
AMD, fulfilling a huge unmet need in the management of this retinal
disease, and these first-in-class therapies will strongly drive the
market growth over the next ten years. The launch of wet AMD
adjunctive therapies will also see a significant change in the
treatment of AMD patients and have a positive impact on the market
growth.
Japan has an increasingly
aging society, which will act as a significant driver of growth in
this market, along with the introduction of novel therapies for both
wet and dry AMD. The wAMD drugs, Fovista and abicipar pegol, are
expected to enter the Japanese AMD market in 2019 and 2023,
respectively, while the dAMD drugs, lampalizumab and emixustat, are
both expected to enter in 2018.
View
Full Report at http://www.marketresearchreports.biz/analysis/247053
Scope
- Overview of Macular Edema
and Macular Degeneration including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2013-2023.
- Analysis of the impact of
key events as well the drivers and restraints affecting Japan Macular
Edema and Macular Degeneration market.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the
competition by understanding the changing competitive landscape for
Macular Edema and Macular Degeneration
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in Japan
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
2.1 Related Reports 14
3 Disease Overview 16
3.1 Macular Degeneration
Overview 16
3.1.1 Etiology and
Pathophysiology 18
3.1.2 Classification 22
3.1.3 Symptoms and Diagnosis
24
3.2 Macular Edema Overview 27
3.2.1 Etiology and
Pathophysiology 28
3.2.2 Classification 31
3.2.3 Symptoms and Diagnosis
32
4 Disease Management 35
4.1 Diagnosis and Treatment
Overview 35
4.1.1 Macular Edema Diagnosis
35
4.1.2 Macular Degeneration
Diagnosis 35
4.1.3 Treatment Guidelines and
Leading Prescribed Drugs 36
4.1.4 Clinical Practice 37
4.2 Japan 50
5 Competitive Assessment 54
5.1 Overview 54
5.2 Product Profiles - Major
Brands 55
5.2.1 Lucentis (ranibizumab)
55
5.2.2 Eylea (aflibercept) 65
5.2.3 Avastin (bevacizumab) 75
5.2.4 Macugen (pegaptanib
sodium) 81
5.2.5 Visudyne (verteporfin)
84
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment